Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel-Reference-Cited by-同舟云学术

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel

Published:2017-11-22 Issue: Volume:8 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Li Jian-Ri,Chiu Kun-Yuan,Wang Shian-Shiang,Yang Cheng-Kuang,Chen Chuan-Shu,Ho Hao-Chung,Hung Chi-Feng,Cheng Chen-Li,Yang Chi-Rei,Chen Cheng-Che,Wang Shu-Chi,Lin Chia-Yen,Chang Chao-Hsiang,Hsu Chiann-Yi,Ou Yen-Chuan

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference17 articles.

1. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N. Engl. J. Med.,2014

2. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel;Chi;Ann. Oncol.,2016

3. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer;Cornford;Eur. Urol.,2017

4. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study;Fizazi;Lancet Oncol.,2012

5. Abiraterone acetate for metastatic prostate cancer in patients with suboptimal biochemical response to hormone induction;Flaig;JAMA Oncol,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan;BMC Cancer;2023-06-13

2. 68Ga-PSMA-11 PET/CT Features Extracted from Different Radiomic Zones Predict Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer;Cancers;2022-10-03

3. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study;Anticancer Research;2022-10

4. Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer;BJU International;2021-10

5. Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate;Prostate Cancer and Prostatic Diseases;2021-02-18